Observation and Safety Analysis of Recombinant Human Urokinase Primary Thrombolysis in Acute Myocardial Infarction  

作　　者：LUYe 

机构地区：[1]Hebei Friendship Hospital, Shijiazhuang 050000, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第9期194-198,共5页

摘　　要：Objective: to observe the effect of recombinant human urokinase prothrombolysis and thrombolysis in the therapy of acute myocardial infarction. Methods: Eighty-six patients with acute myocardial infarction were randomly divided into two groups. The first group was treated with urokinase, and the second group was treated with urokinase. The former was the control group, and the latter was the observation group. The data obtained were observed. Results: according to the analysis of the related indexes of the patients, the observation group is better than the control group, P 0.05;according to the data of the recanalization rate and the time of thrombolytic recanalization, the observation group is better than the control group, P 0.05;according to the analysis of the data obtained from patients with bleeding, the observation group was lower than the control group (p 0.05) , and according to the analysis of the data obtained from adverse reactions, the observation group was lower than the control group (p 0.05);according to the analysis of the quality of life data, the observation group was higher than the control group, P 0.05. Conclusion: in the treatment of patients with acute myocardial infarction, the recombinant human urokinase primary thrombolytic therapy effect is good, which improves the vascular recanalization rate, shortens the thrombolytic recanalization time, reduces the bleeding rate, has less adverse reactions and high quality of life, and the overall effect is better than the urokinase thrombolytic therapy, which is worth learning from.

关 键 词：recombinant human urokinase progen thrombolysis urokinase thrombolysis acute myocardial infarction effect safety 

分 类 号：R542.22[医药卫生—心血管疾病]